Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg".
Press Release Sep 06 2024
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Intimation of Board Meeting scheduled on July 29, 2024
- Press Release May 22 2024
- Intimation of Board Meeting scheduled on May 22, 2024
- Press Release May 10 2024
- Press Release Apr 09 2024
Later from Strides Pharma Science
- Press Release Sep 11 2024
- Press Release Sep 16 2024
- Strides Pharma Science Ltd Press Release Oct 16 2024
- Intimation of Board Meeting scheduled on October 24, 2024
- Press Release Oct 24 2024
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science